Biopharma companies face regulatory, deal delays due to Covid-19

12:14 EDT 26 Mar 2020 | MedCity News

Intercept Pharmaceuticals and bluebird bio said they had encountered regulatory snags at the FDA for their investigational drugs, while Pfizer is pausing most of its clinical trials and delaying completion of a deal with Mylan to create a new company.

Original Article: Biopharma companies face regulatory, deal delays due to Covid-19


More From BioPortfolio on "Biopharma companies face regulatory, deal delays due to Covid-19"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...